Leishmaniasis treatment—a challenge that remains: a review
- First Online:
- Cite this article as:
- Santos, D.O., Coutinho, C.E.R., Madeira, M.F. et al. Parasitol Res (2008) 103: 1. doi:10.1007/s00436-008-0943-2
Leishmaniasis is a disease caused by flagellate protozoan Leishmania spp. and represents an emergent illness with high morbidity and mortality in the tropics and subtropics. Since the discovery of the first drugs for Leishmaniasis treatment (i.e., pentavalent antimonials), until the current days, the search for substances with antileishmanial activity, without toxic effects, and able to overcome the emergence of drug resistant strains still remains as the current goal. This article reports the development of new chemotherapies through the rational design of new drugs, the use of products derived from microorganisms and plants, and treatments related to immunity as new alternatives for the chemotherapy of leishmaniasis.